AC
ZNTL icon

Almitas Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Almitas Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-610,073
Closed -$1.43M – 145
2026
Q1 		$1.43M Hold
610,073
– – 0.32% 54
2025
Q4 		$824K Buy
610,073
+152,751
+33% +$222K 0.18% 65
2025
Q3 		$691K Sell
457,322
-1,141,944
-71% -$1.71M 0.16% 54
2025
Q2 		$1.86M Sell
1,599,266
-111,655
-7% -$147K 0.47% 35
2025
Q1 		$2.72M Buy
1,710,921
+84,025
+5% +$181K 0.9% 20
2024
Q4 		$4.93M Buy
1,626,896
+665,968
+69% +$2.18M 1.08% 18
2024
Q3 		$3.54M Buy
+960,928
New +$3.49M 1.25% 23

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Almitas Capital's ZNTL Position: Q2 2026 in Review

Almitas Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 610,073 shares — an estimated $1.43M sold.

Almitas Capital first reported a position in ZNTL in Q3 2024 and held it in 7 quarters. The position peaked at $4.93M in Q4 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Almitas Capital reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Almitas Capital sold 610,073 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.43M.
  • Almitas Capital first reported a position in Zentalis Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Almitas Capital's Zentalis Pharmaceuticals position peaked at $4.93M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Almitas Capital's 13F filing for Q2 2026, filed 17 Aug 2026.